View More View Less
  • 1 Meram Vocational School, Necmettin Erbakan University, Konya, Turkey
  • | 2 Department of Neurology, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
  • | 3 Department of Neurology, Konya Education and Research Hospital, University of Health Science, Konya, Turkey
  • | 4 Department of Neurology, Abdulkadir Yuksel Hospital, Gaziantep, Turkey
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $752.00

Abstract

Objective

Multiple sclerosis (MS) is a chronic and progressive neurological disease affecting the central nervous system (CNS). Some studies report an association between MS pathogenesis and cytokines. Here, we aimed to determine and evaluate serum kisspeptin-10 level in MS patients and its related clinic parameters.

Materials and Methods

A total of 92 participants, 46 patients with relapsing-remitting MS (mean age, 38.92 ± 14.76; 22 men and 24 women) and 46 healthy controls (mean age, 37.04 ± 15.49; 22 men and 24 women) were enrolled in the study. All MS patients were neurologically examined, and magnetic resonance imaging (MRI) was performed. Clinical data (neuropathic pain, expanded disability status scale (EDSS) score, etc.) and the patients' demographic characteristics were recorded. The serum level of kisspeptin-10 was analyzed by enzyme-linked immunosorbent assay (ELISA) method.

Results

The level of kisspeptin-10 was measured as 2.305 ± 2.781 ng/mL in MS patients and 9.342 ± 9.483 ng/mL in controls. MS patients had significantly lower kisspeptin-10 levels than controls (P = 0.000). Kisspeptin-10 has the highest diagnostic value [Area under curve (AUC) = 0.881, 95% confidence interval (CI), 0.812–0.950] as cut-off value (2.470), sensitivity (80.40%) and specificity (72.87%) in the MS group. Furthermore, the kisspeptin-10 level was negatively correlated with third ventricle diameter (TVD) (P = 0.048) and vitamin D concentration (P = 0.004). No significant difference was determined between kisspeptin-10 and other clinical parameters.

Conclusion

As a potential prognostic biomarker, serum kisspeptin-10 level was significantly lower in patients with MS than in those without. Moreover, we observed negative correlations between vitamin D, TVD size, and kisspeptin-10. We think comprehensive studies are needed to verify and elucidate this issue.

  • 1.

    Popescu BF, Pirko I, Lucchinetti CF. Pathology of multiple sclerosis: where do we stand. Continuum (MinneapMinn). 2013; 19(4): 90121.

    • Search Google Scholar
    • Export Citation
  • 2.

    Gilroy J. Basic neurology. 3rd edition. New York-St.Louis-San Francisco: McGraw-Hill; 2000. pp. 199223.

  • 3.

    Rolak LA. Multiple sclerosis: it's not the disease you thought it was. Clin Med Res 2003; 1(1): 5760. https://doi.org/10.3121/cmr.1.1.57.

    • Search Google Scholar
    • Export Citation
  • 4.

    Solleiro-Villavicencio H, Rivas-Arancibia S. Effect of chronic oxidative stress on neuroinflammatory response mediated by CD4+T Cells in neurodegenerative diseases. Front Cell. Neurosci. 2018; 12:114. https://doi.org/10.3389/fncel.2018.00114.

    • Search Google Scholar
    • Export Citation
  • 5.

    Ascherio A. Environmental factors in multiple sclerosis. Expert Rev Neurother 2013; 13(12 Suppl.): 39. https://doi.org/10.1586/14737175.2013.865866.

    • Search Google Scholar
    • Export Citation
  • 6.

    Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, et al. Environmental and genetic risk factors for MS: an integrated review. Ann Clin Transl Neurol 2019; 6(9): 19051922. https://doi.org/10.1002/acn3.50862.

    • Search Google Scholar
    • Export Citation
  • 7.

    Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325(7): 46772.

    • Search Google Scholar
    • Export Citation
  • 8.

    Vranová HP, Sládková V, Mareš J, Hluštík P, Langová J, Kanovský P. Cystatin C as a marker of degeneration in multiple sclerosis. Neurology 2013; 80(7): P03.241.

    • Search Google Scholar
    • Export Citation
  • 9.

    Olaniyan OT, Meraiyebu AB, Auta KB, Dare JB, Anjorin YD, Shafe MO. Kisspeptin system: a multi-homeostatic system. IOSR J Pharm Biol Sci 2013; 5(4): 87101.

    • Search Google Scholar
    • Export Citation
  • 10.

    Poling MC, Quennell JH, Anderson GM, Kauffman AS. Kisspeptin neurons do not directly signal to RFRP-3 neurons but RFRP-3 may directly modulate a subset of hypothalamic kisspeptin cells in mice. J Neuroendocrinol 2013; 25(10): 87686.

    • Search Google Scholar
    • Export Citation
  • 11.

    Zeydabadi Nejad S, Ramezani Tehrani F, Zadeh-Vakili A. The role of kisspeptin in female reproduction. Int J Endocrinol Metab 2017; 15(3): e44337.

    • Search Google Scholar
    • Export Citation
  • 12.

    Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 2001; 411(6837): 6137.

    • Search Google Scholar
    • Export Citation
  • 13.

    Olbrich T, Ziegler E, Türk G, Schubert A, Emons G, Gründker C. Kisspeptin-10 inhibits bone-directed migration of GPR54-positive breast cancer cells: evidence for a dose-window effect. Gynecol Oncol 2010; 119(3): 571578.

    • Search Google Scholar
    • Export Citation
  • 14.

    Kirby HR, Maguire JJ, Colledge WH, Davenport AP. International union of basic and clinical pharmacology. LXXVII. kisspeptin receptor nomenclature, distribution, and function. Pharmacol Rev 2010; 62(4): 56578.

    • Search Google Scholar
    • Export Citation
  • 15.

    Attard CC. The role of kisspeptin signaling in the hypothalamic-pituitary-gonadal axis. Malta Med J 2017; 29(3): 3036.

  • 16.

    Sato K, Shirai R, Hontani M, Shinooka R, Hasegawa A, Kichise T, et al. Potent vasoconstrictor kisspeptin-10 induces atherosclerotic plaque progression and instability: reversal by its receptor GPR54 antagonist. J Am Heart Assoc 2017; 6(4): e005790. https://doi.org/10.1161/JAHA.117.005790.

    • Search Google Scholar
    • Export Citation
  • 17.

    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33(11): 144452.

    • Search Google Scholar
    • Export Citation
  • 18.

    Polacek H, Kantorova E, Hnilicova P, Grendar M, Zelenak K, Kurca E. Increased glutamate and deep brain atrophy can predict the severity of multiple sclerosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019; 163(1): 4553.

    • Search Google Scholar
    • Export Citation
  • 19.

    Roldan-Valadez E, Garcia-Ulloa AC, Gonzalez-Gutierrez O, Martinez-Lopez M. 3D volumetry comparison using 3T magnetic resonance imaging between normal and adenoma-containing pituitary glands. Neurol India 2011; 59(5): 6969.

    • Search Google Scholar
    • Export Citation
  • 20.

    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46(10): 11213.

    • Search Google Scholar
    • Export Citation
  • 21.

    Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003; 19(5): 30614.

  • 22.

    Alpua M, Turkel Y, Dag E, Kisa U. Apelin-13: a promising biomarker for multiple sclerosis. Ann Indian Acad Neurol 2018; 21(2): 126129.

    • Search Google Scholar
    • Export Citation
  • 23.

    Ghasemi N, Razavi S, Nikzad E. Multiple Sclerosis: pathogenesis, symptoms, diagnoses, and cell-based therapy. Cell J 2017; 19(1): 110. https://doi.org/10.22074/cellj.2016.4867.

    • Search Google Scholar
    • Export Citation
  • 24.

    Racke MK. Immunopathogenesis of multiple sclerosis. Ann Indian Acad Neurol 2009; 12(4): 21520.

  • 25.

    Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2011; 124(2): 7584.

  • 26.

    Islas-Hernandez A, Aguilar-Talamantes HS, Bertado-Cortes B, Mejia-delCastillo GJ, Carrera-Pineda R, Cuevas-Garcia CF, et al. BDNF and Tau as biomarkers of severity in multiple sclerosis. Biomark Med 2018; 12(7): 717726. https://doi.org/10.2217/bmm-2017-0374.

    • Search Google Scholar
    • Export Citation
  • 27.

    Isgrò MA, Caldarella C, Scribano D, Colacicco L, Giannace A, Zuppi C, et al. Is there a role for serum cystatin C as a biomarker of multiple sclerosis. Biochim Clin 2014; 38(3): 21822.

    • Search Google Scholar
    • Export Citation
  • 28.

    Muller M, Esser R, Kötter K, Voss J, Müller A, Stellmes P. Third ventricular enlargement in early stages of multiple sclerosis is a predictor of motor and neuropsychological deficits: a cross-sectional study. BMJ Open 2013; 3:e003582.

    • Search Google Scholar
    • Export Citation
  • 29.

    d’Alessandro A, Mandolesi S, Niglio T, Orsini A, Di Cello P, Pelle F, et al. Increased size of third ventricle in patients with multiple sclerosis and chronic cerebrospinal venous insufficiency. J Vasc Diagn 2014; 2:9197.

    • Search Google Scholar
    • Export Citation
  • 30.

    Hatamian H, Bidabadi E, Seyed Saadat SM, Saadat NS, Kazemnezhad E, Ramezani H, et al. Is serum vitamin D levels associated with disability in patients with newly diagnosed multiple sclerosis. Iran J Neurol 2013; 12(2): 416.

    • Search Google Scholar
    • Export Citation
  • 31.

    Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005; 4(10): 64352. https://doi.org/10.1016/S1474-4422(05)70193-9.

    • Search Google Scholar
    • Export Citation
  • 32.

    Meyer-Moock S, Feng YS, Maeurer M, Dippel FW, Kohlmann T. Systematic literature review and validity evaluation of the expanded disability status scale (EDSS) and the multiple sclerosis functional composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14:58. https://doi.org/10.1186/1471-2377-14-58.

    • Search Google Scholar
    • Export Citation

 

 

The author instruction is available in PDF.

Please, download the file from HERE

 

 

Senior editors

Editor(s)-in-Chief: Rosivall, László

Managing Editor: Berhidi, Anna

Co-editor(s): Koller, Ákos; Lénárd, László; Szénási, Gábor; Radák, Zsolt

Assistant Editor(s): G. Dörnyei (Budapest), Zs. Miklós (Budapest), Gy. Nádasy (Budapest)

Hungarian Editorial Board

  • Benedek, György (Szeged)
  • Benyó, Zoltán (Budapest)
  • Boros, Mihály (Szeged)
  • Chernoch, László (Debrecen)
  • Dank, Magdolna (Budapest)
  • Détári, László (Budapest)
  • Giricz, Zoltán (Budapest)
  • Hamar, János (Budapest)
  • Hantos, Zoltán (Szeged)
  • Hunyady, László (Budapest)
  • Jancsó, Gábor (Szeged)
  • Karádi, Zoltán (Pécs)
  • Palkovits, Miklós (Budapest)
  • Papp, Gyula (Szeged)
  • Pavlik, Gábor (Budapest)
  • Spät, András (Budapest)
  • Szabó, Gyula (Szeged)
  • Szelényi, Zoltán (Pécs)
  • Szollár, Lajos (Budapest)
  • Szücs, Géza (Debrecen)
  • Telegdy, Gyula (Szeged)
  • Toldi, József (Szeged)
  • Tósaki, Árpád (Debrecen)

 

International Editorial Board

  • R. Bauer (Jena)
  • W. Benjelloun (Rabat)
  • A. W. Cowley Jr. (Milwaukee)
  • D. Djuric (Belgrade)
  • C. Fry (London)
  • S. Greenwald (London)
  • O. Hänninen (Kuopio)
  • H. G. Hinghofer-Szalkay (Graz)
  • T. Hortobágyi (Groningen)
  • Gy. Kunos (Richmond)
  • M. Mahmoudian (Tehran)
  • T. Mano (Seki, Gifu)
  • G. Navar (New Orleans)
  • H. Nishino (Nagoya)
  • O. Petersen (Liverpool)
  • U. Pohl (Münich)
  • R. S. Reneman (Maastricht)
  • A. Romanovsky (Phoenix)
  • G. M. Rubanyi (Richmond)
  • T. Sakata (Oita)
  • A. Siddiqui (Karachi)
  • Cs. Szabo (Beverly)
  • E. Vicaut (Paris)
  • N. Westerhof (Amsterdam)
  • L. F. Zhang (Xi'an)

Editorial Office:
Akadémiai Kiadó Zrt.
Prielle Kornélia u. 21–35, H-1117 Budapest, Hungary

Editorial Correspondence:
Physiology International
Semmelweis University, Faculty of Medicine Institute of Pathophysiology
Nagyvárad tér 4, H-1089 Budapest, Hungary
Phone/Fax: +36-1-2100-100
E-mail: pi@semmelweis-univ.hu

Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • EMBASE/Excerpta Medica
  • Global Health
  • Index Copernicus
  • Index Medicus
  • Medline
  • Referativnyi Zhurnal
  • SCOPUS
  • Social Science Citation Index

 

 

2020  
Total Cites 245
WoS
Journal
Impact Factor
2,090
Rank by Physiology 62/81 (Q4)
Impact Factor  
Impact Factor 1,866
without
Journal Self Cites
5 Year 1,703
Impact Factor
Journal  0,51
Citation Indicator  
Rank by Journal  Physiology 67/84 (Q4)
Citation Indicator   
Citable 42
Items
Total 42
Articles
Total 0
Reviews
Scimago 29
H-index
Scimago 0,417
Journal Rank
Scimago Physiology (medical) Q3
Quartile Score  
Scopus 270/1140=1,9
Scite Score  
Scopus Physiology (medical) 71/98 (Q3)
Scite Score Rank  
Scopus 0,528
SNIP  
Days from  172
sumbission  
to acceptance  
Days from  106
acceptance  
to publication  

2019  
Total Cites
WoS
137
Impact Factor 1,410
Impact Factor
without
Journal Self Cites
1,361
5 Year
Impact Factor
1,221
Immediacy
Index
0,294
Citable
Items
34
Total
Articles
33
Total
Reviews
1
Cited
Half-Life
2,1
Citing
Half-Life
9,3
Eigenfactor
Score
0,00028
Article Influence
Score
0,215
% Articles
in
Citable Items
97,06
Normalized
Eigenfactor
0,03445
Average
IF
Percentile
12,963
Scimago
H-index
27
Scimago
Journal Rank
0,267
Scopus
Scite Score
235/157=1,5
Scopus
Scite Score Rank
Physiology (medical) 73/99 (Q3)
Scopus
SNIP
0,38

 

Physiology International
Publication Model Hybrid
Submission Fee none
Article Processing Charge 1100 EUR/article
Printed Color Illustrations 40 EUR (or 10 000 HUF) + VAT / piece
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2021 Online subsscription: 632 EUR / 788 USD 
Print + online subscription: 736 EUR / 920 USD
Subscription fee 2022 Online subsscription: 644 EUR / 806 USD
Print + online subscription: 752 EUR / 942 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Physiology International
Language English
Size B5
Year of
Foundation
2006 (1950)
Publication
Programme
2021 Volume 108
Volumes
per Year
1
Issues
per Year
4
Founder Magyar Tudományos Akadémia
Founder's
Address
H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher
Chief Executive Officer, Akadémiai Kiadó
ISSN 2498-602X (Print)
ISSN 2677-0164 (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Apr 2021 0 0 0
May 2021 0 0 0
Jun 2021 0 0 0
Jul 2021 50 6 7
Aug 2021 44 3 3
Sep 2021 34 0 0
Oct 2021 0 0 0